SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the quarterly period ended June 30, 2003
OR
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the transition period from to
Commission file number 0-32501
MacroPore Biosurgery, Inc.
(Exact name of registrant as specified in its charter.)
|
Delaware |
|
33-0827593 |
|
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer Identification No.) |
|
|
|
|
|
6740 Top Gun Street, San Diego, California |
|
92121 |
|
(Address of principal executive offices) |
|
(Zip code) |
Registrant’s telephone number, including area code: (858) 458-0900
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days: YES ý NO o
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). YES o NO ý
As of July 22, 2003, there were 14,585,599 shares of MacroPore Biosurgery, Inc. common stock outstanding.
MACROPORE BIOSURGERY, INC.
INDEX
i
Independent Accountants’ Review Report
The Board of Directors and Shareholders
MacroPore Biosurgery, Inc.:
We have reviewed the accompanying consolidated condensed balance sheet of MacroPore Biosurgery, Inc. and subsidiaries as of June 30, 2003, and the related consolidated condensed statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2003 and 2002, and the consolidated condensed statements of cash flows for the six months ended June 30, 2003 and 2002. These condensed consolidated financial statements are the responsibility of the Company’s management.
We conducted our reviews in accordance with standards established by the American Institute of Certified Public Accountants. A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with auditing standards generally accepted in the United States of America, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.
Based on our reviews, we are not aware of any material modifications that should be made to the consolidated condensed financial statements referred to above for them to be in conformity with accounting principles generally accepted in the United States of America.
We have previously audited, in accordance with auditing standards generally accepted in the United States of America, the consolidated balance sheet of MacroPore Biosurgery, Inc. and subsidiaries as of December 31, 2002, and the related consolidated statements of operations and comprehensive income (loss), stockholders’ equity, and cash flows for the year then ended (not presented herein); and in our report dated March 7, 2003, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying consolidated condensed balance sheet as of December 31, 2002, is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.
|
|
/s/ KPMG LLP |
|
|
|
|
|
|
|
San Diego, California |
|
|
August 11, 2003 |
|
1
MACROPORE BIOSURGERY, INC.
CONSOLIDATED CONDENSED BALANCE SHEETS
|
|
|
June 30, |
|
December
31, |
|
||
|
|
|
(Unaudited) |
|
|
|
||
|
Assets |
|
|
|
|
|
||
|
Current assets: |
|
|
|
|
|
||
|
Cash and cash equivalents |
|
$ |
2,088,000 |
|
$ |
5,108,000 |
|
|
Short-term investments, available-for-sale |
|
16,608,000 |
|
19,875,000 |
|
||
|
Accounts receivable, net of allowance for doubtful accounts of $65,000 and $50,000 in 2003 and 2002, respectively |
|
1,186,000 |
|
1,238,000 |
|
||
|
Inventories |
|
1,054,000 |
|
1,150,000 |
|
||
|
Other current assets |
|
575,000 |
|
843,000 |
|
||
|
|
|
|
|
|
|
||
|
Total current assets |
|
21,511,000 |
|
28,214,000 |
|
||
|
|
|
|
|
|
|
||
|
Property and equipment, net |
|
3,471,000 |
|
3,626,000 |
|
||
|
Other assets |
|
443,000 |
|
562,000 |
|
||
|
Goodwill and intangibles, net |
|
7,195,000 |
|
6,917,000 |
|
||
|
|
|
|
|
|
|
||
|
Total assets |
|
$ |
32,620,000 |
|
$ |
39,319,000 |
|
|
|
|
|
|
|
|
||
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
||
|
Current liabilities: |
|
|
|
|
|
||
|
Accounts payable and accrued expenses |
|
$ |
1,994,000 |
|
$ |
2,502,000 |
|
|
Current portion of long-term obligations |
|
426,000 |
|
410,000 |
|
||
|
|
|
|
|
|
|
||
|
Total current liabilities |
|
2,420,000 |
|
2,912,000 |
|
||
|
|
|
|
|
|
|
||
|
Deferred gain on sale of assets, related party |
|
8,798,000 |
|
9,623,000 |
|
||
|
Deferred revenue |
|
22,000 |
|
19,000 |
|
||
|
Long-term obligations, less current portion |
|
581,000 |
|
770,000 |
|
||
|
|
|
|
|
|
|
||
|
Total liabilities |
|
11,821,000 |
|
13,324,000 |
|
||
|
|
|
|
|
|
|
||
|
Stockholders’ equity: |
|
|
|
|
|
||
|
Preferred stock, $0.001 par value; 5,000,000 shares authorized; -0- shares issued and outstanding in 2003 and 2002 |
|
— |
|
— |
|
||
|
Common stock, $0.001 par value; 95,000,000 shares authorized; 16,717,581 and 16,646,664 shares issued and 14,535,599 and 14,527,681 shares outstanding in 2003 and 2002, respectively |
|
17,000 |
|
17,000 |
|
||
|
Additional paid-in capital |
|
74,750,000 |
|
74,730,000 |
|
||
|
Unearned compensation |
|
(635,000 |
) |
(1,057,000 |
) |
||
|
Accumulated deficit |
|
(45,441,000 |
) |
(40,102,000 |
) |
||
|
Treasury stock, at cost |
|
(7,999,000 |
) |
(7,752,000 |
) |
||
|
Accumulated other comprehensive income |
|
107,000 |
|
159,000 |
|
||
|
|
|
|
|
|
|
||
|
Total stockholders’ equity |
|
20,799,000 |
|
25,995,000 |
|
||
|
|
|
|
|
|
|
||
|
Total liabilities and stockholders’ equity |
|
$ |
32,620,000 |
|
$ |
39,319,000 |
|
SEE NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
2
MACROPORE BIOSURGERY, INC.
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(UNAUDITED)
|
|
|
For the
Three Months |
|
For the Six
Months |
|
||||||||
|
|
|
2003 |
|
2002 |
|
2003 |
|
2002 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Revenues: |
|
|
|
|
|
|
|
|
|
||||
|
Sales to related party |
|
$ |
2,585,000 |
|
$ |
2,700,000 |
|
$ |
4,191,000 |
|
$ |
3,797,000 |
|
|
Sales to third parties |
|
318,000 |
|
7,000 |
|
641,000 |
|
20,000 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
2,903,000 |
|
2,707,000 |
|||||||||